Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
European Journal of Cancer & Clinical Oncology
|
August 1, 1983
A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy
A W Hutcheon, J B Palmer, M Soukop, et al.
British Journal of Cancer
|
November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist
J Cassidy, V Raina, C Lewis, et al.
Journal of Clinical Pathology
|
March 1, 1985
Functional and structural changes of the human proximal small intestine after cytotoxic therapy
D Cunningham, R J Morgan, P R Mills, et al.
British Journal of Cancer
|
March 27, 2001
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
F H Blackhall, M Ranson, J A Radford, et al.
Biochimica Et Biophysica Acta
|
October 4, 1984
Low-density lipoprotein metabolism in mice with soft tissue tumours
S A Hynds, J Welsh, J M Stewart, et al.
Cancer Research
|
December 15, 1987
Phase I and pharmacokinetic study of flavone acetic acid
D J Kerr, S B Kaye, J Cassidy, et al.
Lancet (London, England)
|
August 24, 1991
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy
A L Jones, A S Hill, M Soukop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1987
Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast
R C Leonard, M A Cornbleet, S B Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1994
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial
G C Wishart, D Bissett, J Paul, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1986
TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage
D Cunningham, M Soukop, N L Gilchrist, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
European Journal of Cancer & Clinical Oncology
|
August 1, 1983
A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy
A W Hutcheon, J B Palmer, M Soukop, et al.
British Journal of Cancer
|
November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist
J Cassidy, V Raina, C Lewis, et al.
Journal of Clinical Pathology
|
March 1, 1985
Functional and structural changes of the human proximal small intestine after cytotoxic therapy
D Cunningham, R J Morgan, P R Mills, et al.
British Journal of Cancer
|
March 27, 2001
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
F H Blackhall, M Ranson, J A Radford, et al.
Biochimica Et Biophysica Acta
|
October 4, 1984
Low-density lipoprotein metabolism in mice with soft tissue tumours
S A Hynds, J Welsh, J M Stewart, et al.
Cancer Research
|
December 15, 1987
Phase I and pharmacokinetic study of flavone acetic acid
D J Kerr, S B Kaye, J Cassidy, et al.
Lancet (London, England)
|
August 24, 1991
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy
A L Jones, A S Hill, M Soukop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1987
Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast
R C Leonard, M A Cornbleet, S B Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1994
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial
G C Wishart, D Bissett, J Paul, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1986
TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage
D Cunningham, M Soukop, N L Gilchrist, et al.
Page
of 11